Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by 99942Apophison Dec 07, 2021 11:03am
566 Views
Post# 34206268

RE:RE:RE:Summary of Results for Newbies

RE:RE:RE:Summary of Results for Newbiesmenoalittle wrote
]after reviewing a few summaries posted here of results this far, it appears there was mention made of none of the participants having received a second treatment... which I don't think is totally accurate.

furthermore, there was no mention of the treatment(s) durability.

now, I know there was news of the 2 from phase 2 being CR at 450 days. and, unless I'm mistaken... I seem to recall reading somewhere (probably a post on this board) that there might be 4 that are CR at 450 days.  I haven't had time to verify what the truth here actually is. 

Would someone that has the scope on it be so kind as to clarify this for me? TIA



It was from the recent newsletter menoalittle 4 patients at 360 & 450 days.



Assessment Day*
 
90 Days 180 Days 270 Days 360 Days 450 Days
# % # % # % # % # %
Complete Response (“CR”) 14 42 % 7 21 % 7 21 % 4 12 % 4 12 %
Partial Response (“PR”) 4 12 % 5 15 % 2 6 % 4 12 % 2 6 %
Pending 7 21 % 13 39 % 15 45 % 16 48 % 17 52 %
No Response (“NR”) 8 24 % 8 24 % 9 27 % 9 27 % 10 30 %
Total Treated* 33 100 % 33 100 % 33 100 % 33 100 % 33 100 %

*Includes three (3) patients treated at the Therapeutic Dose form Phase Ib NMIBC Clinical Study (2-CR and 1- NR at 90, 180, 270, 360, 450 days)

An analysis of the Study II clinical data (with 3 patients from Study Ib) provides the following interim assessments:


<< Previous
Bullboard Posts
Next >>